Ashling Wahner

Dr Baggio on Prognostic Patterns of CNS Relapse in LBCL

July 11th 2025

Diva Baggio, MBBS, discusses findings from an international, multicenter study evaluating relapse patterns in patients with CNS relapse of LBCL.

Dr Tan on the Clinical Relevance of T-DXd in HER2-Low/Ultralow Metastatic Breast Cancer

July 11th 2025

Antoinette Tan, MD, MHS, discusses the implications of the DESTINY-Breast06 trial of T-DXd vs chemotherapy in HER2-low or -ultralow breast cancer.

Glofitamab Plus Pirtobrutinib Yields High Activity, Tolerability in Covalent BTK Inhibitor–Exposed MCL

July 11th 2025

Results from the GoldiLox trial showed high complete and MRD-negative responses with glofitamab plus pirtobrutinib in covalent BTK inhibitor–exposed MCL.

Dr D'Amato on Efficacy Data With Olaparib Plus Temozolomide in Advanced Uterine Leiomyosarcoma

July 10th 2025

Gina Z. D’Amato, MD, shares her interpretation of efficacy outcomes from the negative Alliance A092104 trial in advanced uterine leiomyosarcoma.

Toripalimab Plus De-Intensified Chemo Represents the Potential Future of Nasopharyngeal Cancer Management: With Justine Bruce, MD

July 10th 2025

Dr Bruce discusses treatment strategies for nasopharyngeal cancer, including how first-line toripalimab plus chemotherapy has shown improved OS.

Dr Deng on the Effects of MSH6 on PARP Inhibitor Sensitivity in Ovarian Cancer

July 10th 2025

Ou Deng, PhD, discussed findings from a study investigating MSH6-modulated PARP inhibitor sensitivity in BRCA-proficient, high-grade serous ovarian cancer.

Dr Ganti on the Importance of Molecular Testing in NSCLC

July 10th 2025

Apar Kishor Ganti, MD, discusses the importance of molecular testing in NSCLC and the profiling capabilities of the Oncomine DX Express Test.

FDA Releases CRLs for Previous Drug and Biologic Product Applications

July 10th 2025

The FDA has published a collection of complete response letters that were seeking the approval of drugs or biologic products between 2020 and 2024.

Enzalutamide Plus Leuprolide Yields OS Benefit in nmHSPC With Biochemical Recurrence

July 10th 2025

The combination of enzalutamide and leuprolide improved OS vs leuprolide alone in nmHSPC with high-risk biochemical recurrence at high risk for metastasis.

European Commission Approves First-Line Tislelizumab Plus Chemo for Metastatic Nasopharyngeal Carcinoma

July 10th 2025

The European Commission has approved tislelizumab plus gemcitabine/cisplatin for adults with recurrent or metastatic nasopharyngeal carcinoma.

Targeted Therapies Broaden Treatment Options for CDK4/6 Inhibitor–Resistant, HR+ Breast Cancer

July 10th 2025

Kevin Kalinsky, MD, MS, FASCO, discusses the importance of optimizing endocrine-based therapies in hormone receptor–positive metastatic breast cancer.

HER2DX Assay Predicts pCR Following Neoadjuvant THP in HER2+ Breast Cancer

July 10th 2025

HER2DX genomic scoring predicted pCR after neoadjuvant THP in a high-risk subgroup of patients with HER2-positive early breast cancer.

Decitabine/Cedazuridine Plus Venetoclax sNDA Under FDA Review for Newly Diagnosed AML

July 9th 2025

Decitabine plus cedazuridine and venetoclax is under review for patients with newly diagnosed AML who are ineligible for intensive induction chemotherapy.

How Enthusiasm for Science and Global Change Culminates in Wide-Reaching Opportunities to Improve Cancer Care: D. Ross Camidge, MD, PhD; and Catharine Young, PhD

July 9th 2025

Camidge and Young discuss Young's career, which combined her passions for science and global engagement and led her to a Cancer Moonshot leadership role.

Dr Vogel on the European Commission’s Marketing Authorization of Zanidatamab for HER2+ Biliary Tract Cancer

July 9th 2025

Dr Arora on A Retrospective Analysis of Temporal Trends to Assess MCL Incidence From 2000-2021

July 9th 2025

Ruby Arora, MD, discusses the design of a retrospective analysis of temporal trends in MCL incidence from 2000 to 2021.

SUPRAME Trial Seeks to Establish IMA203 as the First TCR-Based Therapy for Cutaneous Melanoma

July 9th 2025

The phase 3 SUPRAME trial is comparing IMA203 vs investigator’s choice of therapy in patients with pretreated unresectable or metastatic cutaneous melanoma.

Bria-IMT Plus Checkpoint Inhibition Leads to 52% 1-Year OS Rate in Heavily Pretreated Metastatic Breast Cancer

July 8th 2025

Bria-IMT plus checkpoint inhibition displayed a potential overall survival benefit in heavily pretreated, hormone receptor–positive breast cancer.

MB-101 Receives FDA Orphan Drug Designation for Astrocytoma and Glioblastoma

July 8th 2025

The FDA granted orphan drug designation to MB-101 for recurrent diffuse and anaplastic astrocytoma and glioblastoma.

FDA Grants Orphan Drug Designation to FF-10832 for Biliary Tract Cancer

July 8th 2025

FF-10832—an investigational liposomal formulation of gemcitabine—has received orphan drug designation from the FDA for biliary tract cancer.